Inclisiran + Placebo
Phase 3Active 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Atherosclerotic Cardiovascular Disease
Conditions
Atherosclerotic Cardiovascular Disease
Trial Timeline
Oct 30, 2018 → Dec 1, 2049
NCT ID
NCT03705234About Inclisiran + Placebo
Inclisiran + Placebo is a phase 3 stage product being developed by Novartis for Atherosclerotic Cardiovascular Disease. The current trial status is active. This product is registered under clinical trial identifier NCT03705234. Target conditions include Atherosclerotic Cardiovascular Disease.
What happened to similar drugs?
8 of 20 similar drugs in Atherosclerotic Cardiovascular Disease were approved
Approved (8) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06597006 | Phase 3 | Recruiting |
| NCT06597019 | Phase 3 | Recruiting |
| NCT04659863 | Phase 3 | Completed |
| NCT04652726 | Phase 3 | Completed |
| NCT03705234 | Phase 3 | Active |
Competing Products
20 competing products in Atherosclerotic Cardiovascular Disease